Arjun Puranik, Patrick J. Lenehan, Eli Silvert, Michiel J. M. Niesen, Juan Corchado-Garcia, John C. O’Horo: Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv, 8.8.2021. doi:10.1101/2021.08.06.21261707v1.full. Artikkelin verkkoversio. en
Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, Nickilou Y. Krigbaum, Arthur W. Wallace: Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021. medRxiv, 2021. doi:https://doi.org/10.1101/2021.10.13.21264966. Artikkelin verkkoversio. Viitattu 22.10.2021. en
Denis Y. Logunov ym.: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet, 2.2.2021, nro 0. doi:10.1016/S0140-6736(21)00234-8. ISSN 0140-6736. Artikkelin verkkoversio. English
Enrico M. Bucci, Johannes Berkhof, André Gillibert, Gowri Gopalakrishna, Raffaele A. Calogero, Lex M. Bouter: Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. The Lancet, 22.5.2021, nro 397, s. 1881–1883. PubMed:33991475. doi:10.1016/S0140-6736(21)00899-0. ISSN 0140-6736. Artikkelin verkkoversio. English
Yanjun Zhang ym.: Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 17.11.2020, nro 0. PubMed:33217362. doi:10.1016/S1473-3099(20)30843-4. ISSN 1473-3099. Artikkelin verkkoversio. English
Arjun Puranik, Patrick J. Lenehan, Eli Silvert, Michiel J. M. Niesen, Juan Corchado-Garcia, John C. O’Horo: Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv, 8.8.2021. doi:10.1101/2021.08.06.21261707v1.full. Artikkelin verkkoversio. en
Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, Nickilou Y. Krigbaum, Arthur W. Wallace: Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021. medRxiv, 2021. doi:https://doi.org/10.1101/2021.10.13.21264966. Artikkelin verkkoversio. Viitattu 22.10.2021. en
Enrico M. Bucci, Johannes Berkhof, André Gillibert, Gowri Gopalakrishna, Raffaele A. Calogero, Lex M. Bouter: Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. The Lancet, 22.5.2021, nro 397, s. 1881–1883. PubMed:33991475. doi:10.1016/S0140-6736(21)00899-0. ISSN 0140-6736. Artikkelin verkkoversio. English
Yanjun Zhang ym.: Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 17.11.2020, nro 0. PubMed:33217362. doi:10.1016/S1473-3099(20)30843-4. ISSN 1473-3099. Artikkelin verkkoversio. English
Denis Y. Logunov ym.: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet, 2.2.2021, nro 0. doi:10.1016/S0140-6736(21)00234-8. ISSN 0140-6736. Artikkelin verkkoversio. English
Enrico M. Bucci, Johannes Berkhof, André Gillibert, Gowri Gopalakrishna, Raffaele A. Calogero, Lex M. Bouter: Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. The Lancet, 22.5.2021, nro 397, s. 1881–1883. PubMed:33991475. doi:10.1016/S0140-6736(21)00899-0. ISSN 0140-6736. Artikkelin verkkoversio. English
Yanjun Zhang ym.: Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 17.11.2020, nro 0. PubMed:33217362. doi:10.1016/S1473-3099(20)30843-4. ISSN 1473-3099. Artikkelin verkkoversio. English
Denis Y. Logunov ym.: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet, 2.2.2021, nro 0. doi:10.1016/S0140-6736(21)00234-8. ISSN 0140-6736. Artikkelin verkkoversio. English
Enrico M. Bucci, Johannes Berkhof, André Gillibert, Gowri Gopalakrishna, Raffaele A. Calogero, Lex M. Bouter: Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. The Lancet, 22.5.2021, nro 397, s. 1881–1883. PubMed:33991475. doi:10.1016/S0140-6736(21)00899-0. ISSN 0140-6736. Artikkelin verkkoversio. English
Yanjun Zhang ym.: Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 17.11.2020, nro 0. PubMed:33217362. doi:10.1016/S1473-3099(20)30843-4. ISSN 1473-3099. Artikkelin verkkoversio. English